CoChat

Peripheral F2‐isoprostanes and F4‐neuroprostanes are not increased in Alzheimer's disease

Montine, Thomas J., Quinn, Joseph F., Milatovic, Dejan, Silbert, Lisa C., Dang, Theresa, Sanchez, Stephanie, Terry, Erin, Roberts, L. Jackson, Kaye, Jeffrey A., Morrow, Jason D. · 2002 · Annals of Neurology
Cited by 155

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Quantitative biomarkers of oxidative damage, such as the F 2‐isoprostanes (IsoPs) and F 4‐neuroprostanes (F 4‐NeuroPs), may be useful in assessing progression and response to therapeutics in patients with Alzheimer's disease. F 2‐IsoPs and F 4‐NeuroPs are reproducibly increased in brain and cerebrospinal fluid of Alzheimer's disease patients; however, results in blood and urine have been conflicting. We tested the hypothesis that F 2‐IsoPs and F 4‐NeuroPs in plasma or urine quantitatively reflect oxidative damage to the central nervous system. Our results showed that urine levels of F 2‐IsoPs or their major metabolite were not significantly different between 56 Alzheimer's disease patients and 34 controls. In addition, urine and cerebrospinal fluid F 2‐IsoP levels in 32 Alzheimer's disease patients did not correlate. Supporting these conclusions, elevated rat cerebral F 2‐IsoPs and F 4‐NeuroPs after systemic exposure to kainic acid were not associated with a significant change in their plasma or urine levels. These results show that plasma and urine F 2‐IsoPs and F 4‐NeuroPs do not accurately reflect central nervous system levels of these biomarkers and are not reproducibly elevated in body fluids outside of central nervous system in Alzheimer's disease patients. These results should guide the organization of clinical trials now being planned for patients with Alzheimer's disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.10272

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 155

Metadata

Authors
Montine, T. J., Quinn, J. F., Milatovic, D., Silbert, L. C., Dang, T., Sanchez, S., Terry, E., Roberts, L. J., Kaye, J. A., & Morrow, J. D.
Venue
Annals of Neurology
Publisher
Wiley
Published
2002-07-23
Volume
52
Issue
2
Pages
175-179
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W2055021833
Cited by
155
References
1
FWCI
5.69
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Peripheral F2‐isoprostanes and F4‐neuroprostanes are not increased in Alzheimer's disease. https://app.cochat.ai/papers/10.1002/ana.10272
The paper
Montine, T. J., Quinn, J. F., Milatovic, D., Silbert, L. C., Dang, T., Sanchez, S., Terry, E., Roberts, L. J., Kaye, J. A., & Morrow, J. D. (2002). Peripheral F2‐isoprostanes and F4‐neuroprostanes are not increased in Alzheimer's disease. Annals of Neurology. https://doi.org/10.1002/ana.10272

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.